Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01239381 · ClinicalTrials.gov registry record · NA

Individualized Stereotactic Body Radiotherapy of Liver Metastases

A NA study of Solid Tumor and Liver Metastases, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
92
Enrollment target
2
Study locations

NCT01239381 is a NA study of Solid Tumor and Liver Metastases that has completed, run by Massachusetts General Hospital. The registered enrollment target is 92 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01239381, a NA study of Solid Tumor and Liver Metastases, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
92 participants
Enrollment target
2
Study locations

Study Summary

Stereotactic body radiation therapy (SBRT) is a technique that is used to deliver radiation, to sites in the body. All participants in this study will be treated with SBRT using proton beam radiation. Proton beam radiation uses tiny particles to deliver radiation to tumors. The purpose of this research study is to determine if SBRT with protons will prevent tumor growth and reduce the treatment side effects for liver metastases.

Interventions

  • RADIATION Stereotactic body radiotherapy-proton

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institue - Boston

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2010-10-05
Est. Completion 2017-09-01
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT01239381

The ClinicalTrials.gov registry entry for NCT01239381 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (58% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic body radiotherapy-proton is the first listed.

NCT01239381 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01239381 about?

NCT01239381 is a clinical study titled "Individualized Stereotactic Body Radiotherapy of Liver Metastases". Stereotactic body radiation therapy (SBRT) is a technique that is used to deliver radiation, to sites in the body. All participants in this study will be treated with SBRT using proton beam radiation. Proton beam radiation uses tiny particles to deliver radiation to tumors. The purpose of this resea...

What is the current status of trial NCT01239381?

This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2010-10-05. Estimated completion is 2017-09-01.

What conditions does trial NCT01239381 study?

This clinical trial studies the following conditions: Solid Tumor, Liver Metastases.

What interventions are being tested in trial NCT01239381?

The interventions under investigation include: Stereotactic body radiotherapy-proton (RADIATION).

Who is sponsoring clinical trial NCT01239381?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01239381 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.